ArticleEvidence-based medicine2017

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder.

Kim Boesen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.